Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | B2M negative |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
B2M negative | melanoma | predicted - resistant | Nivolumab | Case Reports/Case Series | Actionable | In a clinical case study, loss of B2m protein expression was identified during and after disease progression in a melanoma patient harboring B2M loss of heterozygosity (LOH), whose disease briefly responded to Opdivo (nivolumab) treatment (PMID: 29070816). | 29070816 |